100 results on '"Leighl, N."'
Search Results
2. PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
3. Phase I Trial of Concurrent Talazoparib and Consolidative Thoracic Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer
4. FP03.03 Clinical Activity of BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer.
5. Survival Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated with Consolidative Thoracic Radiotherapy at a Tertiary Cancer Center
6. 170P Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) + platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)
7. 27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe
8. 19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
9. 30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
10. EP14.05-009 LUMINANCE: A Phase IIIb Study of Durvalumab + Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)
11. P59.17 EGFR Mutation Status, Liver Metastasis, and Overall Survival in Advanced Lung Adenocarcinoma Patients
12. P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
13. P45.09 Real-World Sequencing of ALK-TKIs in Advanced Stage ALK-positive NSCLC patients in Canada
14. P45.07 Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK+ NSCLC
15. P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival
16. FP12.07 Clinico-demographic Factors, EGFR status and their association with Stage at Diagnosis in Lung Adenocarcinoma Patients
17. FP12.01 PD-L1 Assessment in Cytology is Comparable to Histology in Predicting Treatment Response to Checkpoint Inhibitors in NSCLC
18. FP04.01 Nivolumab 480 mg Every 4 Weeks as De Novo Second-line Treatment for Advanced Non-Small Cell Lung Cancer: CheckMate 907
19. FP01.03 Prevalence, Treatment Patterns and Long-Term Clinical Outcomes of Patients with EGFR Positive Resected Stage IB-IIIA NSCLC
20. MA12.03 A Thoracic Cancers International COVID 19 Collaboration Survey on Patients’ Perceptions of COVID-19 (Teravolt-Paper)
21. MA08.02 Outcomes of Early Stage ALK-positive NSCLC patients in a Real-World Cohort
22. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer
23. OA08.04 Validation of Scalable, Automated Data Extraction in an Advanced Lung Cancer Patient Population
24. 191TiP Accelerating lung cancer diagnosis through liquid biopsy
25. 144P Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting
26. 143P Physician perceptions of barriers to epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC)
27. 135P The real-world use of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor mutated (EGFRm) advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC) patients
28. 77TiP From liquid biopsy to cure: Using CtDNA detection of minimal residual disease to identify patients for curative therapy after non-small cell lung cancer (NSCLC) resection
29. P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System
30. P76.84 EGFR Status, Risk Factors for Brain Metastases and Overall Survival in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
31. P35.03 Methylation Signatures Associated with T790M Status in Progressive NSCLC
32. P14.24 Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC
33. P14.09 Early Expansion of M-MDSCs and High Plasma TSLP levels as Predictors of Primary Resistance to PD1 Inhibitors in Metastatic NSCLC
34. OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
35. FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study
36. FP03.03 Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer
37. EP1.16-05 Real World Outcomes of Advanced NSCLC Patients with Liver Metastases
38. EP1.04-24 Smoking History May Help Predict Immunotherapy Response in PDL1+ Lung Cancer Patients
39. EP1.01-40 Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy - A Nepalese Cohort
40. EP1.01-30 Clinico-Pathological Profile of Adenocarcinoma of the Lung – A Prospective Study in a Nepalese Population
41. P2.16-05 Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System
42. P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA
43. P2.03-37 Genomic Landscape of EGFR/ALK Wild-Type Lung Adenocarcinomas in Never-Smokers and Importance of Epithelial-Mesenchymal-Transition
44. P2.03-11 Impact of Ethnicity on Outcome in Never Smokers with EGFR and ALK Wildtype (EGFR/ALK-Wildtype) Lung Adenocarcinomas
45. P1.16-07 Real World Evidence of the Impact of Immunotherapy in Patients with Advanced Lung Cancer
46. P1.14-07 Genomic Profiling of Liquid Biopsies During 2nd/3rd Generation ALK Inhibitor Therapy to Identify Novel Mechanisms of Resistance
47. P1.10-05 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors
48. P1.01-70 Dominant Circulating Myeloid Populations Are Associated with Poor Response in NSCLC Treated with 1st Line PD-1 Monotherapy
49. P1.01-30 Non-Small Cell Lung Cancer (NSCLC) Next Generation Sequencing (NGS): Integrating Genomic Sequencing into a Publicly Funded Health Care Model
50. MA18.07 Identification of Neuroendocrine Transformation in Anaplastic Lymphoma Kinase Rearranged (ALK+) Tumors After Tyrosine Kinase Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.